Skip to search formSkip to main contentSkip to account menu

28 ACTUAT Teriparatide 0.02 MG/ACTUAT Pen Injector [Forteo]

Known as: Teriparatide 250 ug in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Forteo], Forteo 20 MCG/ACTUAT Pen Injector, 28 ACTUAT, FORTEO 20 MCG/Dose in 28 Dose Pen Injector 
National Institutes of Health

Related topics

Related topics

11 relations
Acetic AcidForteoHydrochloric AcidMannitol

Broader (1)

Teriparatide Pen Injector [Forteo]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
Background: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal… 
2017
2017
Osteoporosis as it Affects Men, Andropausal and Senior Males
Osteoporosis (OP) is a condition that involves bone, and can potentially affect the whole skeleton. OP renders thinning of bone… 
2016
2016
Relative bioavailability between two teriparatide formulations in healthy volunteers.
OBJECTIVE To compare the pharmacokinetics, relative bioavailability (RB), immunogenicity, and safety after a single dose of test… 
2015
2015
Validation of an ultrasensitive LC-MS/MS method for PTH 1-34 in porcine plasma to support a solid dose PK study.
BACKGROUND The bioanalysis of Teriparatide (PTH 1-34) is extremely challenging due to the low plasma concentrations present at a… 
2014
2014
Teriparatide (Forteo®) no tratamento da osteoporose grave - NT 94 2014
2014
2014
Teriparatide (Forteo®) no tratamento da osteoporose
Review
2012
Review
2012
Spotlight on Teriparatide in Osteoporosis
Recombinant teriparatide (Forteo®; Forsteo®) is an anabolic (bone-forming) agent. Studies have shown that subcutaneous… 
2011
2011
Osteoporosis treatment: an evidence-based approach.
Osteoporosis is a disease that results in decreased bone mass and quality of bone, which may lead to fracture. Clinicians need to… 
Review
2003
Review
2003
Patent developments in anabolic agents for treatment of bone diseases
A review of the patent literature encompassing the past 3 years (~ 2000 – 2003) in the area of bone anabolic therapies for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)